BioSpace News Archive

MediWound Ltd. announced a positive outcome from a planned interim sample size re-estimation of its ongoing EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers, designed to assess the safety and efficacy of EscharEx compared to gel vehicle and non-surgical standard-of-care.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.

Biofidelity Ltd, the cancer diagnostics company, announces the opening of its US headquarters in Research Triangle Park, North Carolina, expanding its presence in the key US market ahead of its first product launch later this year.

Bio-Techne Corporation and PROGEN announced the launch of the Simple Plex™ Adeno-Associated Virus viral titer assay for AAV2 total capsid quantification.

Synthetic Biologics, Inc. announced that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, and to host a conference call the same day at 4:30 p.m. ET.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported financial results for the second quarter ended June 30, 2021.

InMode Ltd., a leading global provider of innovative medical technologies, announced its consolidated financial results for the second quarter ended June 30, 2021.

Alkermes plc reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021.

Karyopharm Therapeutics Inc. announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO®, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.

PYC Therapeutics, a biotechnology company combining two complementary platform technologies to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, announced a second quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.